DANYELZA
Total Payments
$2.4M
Transactions
576
Doctors
312
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 195 | 130 |
| 2023 | $540,838 | 151 | 108 |
| 2022 | $534,023 | 158 | 102 |
| 2021 | $248,704 | 72 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 88 | 77.9% |
| Consulting Fee | $459,231 | 97 | 19.1% |
| Honoraria | $38,425 | 12 | 1.6% |
| Food and Beverage | $26,503 | 370 | 1.1% |
| Travel and Lodging | $3,411 | 5 | 0.1% |
| Grant | $2,500 | 3 | 0.1% |
| Entertainment | $24.35 | 1 | 0.0% |
Payments by Type
Research
$1.9M
88 transactions
General
$530,095
488 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NAXITAMAB ADDED TO INDUCTION FOR NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA | Y-mAbs Therapeutics, Inc. | $1.0M | 0 |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Y-mAbs Therapeutics, Inc. | $219,155 | 0 |
| A PHASE II STUDY OF HUMANIZED MONOCLONAL ANTIBODY 3F8 (HU3F8) WITH GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN THE TREATMENT OF RECURRENT OSTEOSARCOMA | Y-mAbs Therapeutics, Inc. | $206,323 | 0 |
| TARGETING GD2 IN TRIPLE-NEGATIVE BREAST CANCER USING NAXITAMAB AND ACTIVATED NATURAL KILLER CELLS | Y-mAbs Therapeutics, Inc. | $109,324 | 0 |
| 177LU-DTPA-OMBURTAMAB RADIOIMMUNOTHERAPY FOR RECURRENT OR REFRACTORY MEDULLOBLASTOMA | Y-mAbs Therapeutics, Inc. | $97,200 | 0 |
| Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastom | Y-mAbs Therapeutics, Inc. | $63,000 | 0 |
| A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW | Y-mAbs Therapeutics, Inc. | $43,409 | 3 |
| PHASE 1 TRIAL WITH GD2-SADA:177LU-DOTA DRUG COMPLEX IN PATIENTS WITH RECURRENT OR REFRACTORY METASTATIC SOLID TUMORS KNOWN TO EXPRESS GD2, INCLUDING SMALL CELL LUNG CANCER, SARCOMA AND MALIGNANT MELANOMA | Y-mAbs Therapeutics, Inc. | $42,500 | 0 |
| A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | Y-mAbs Therapeutics, Inc. | $18,965 | 2 |
| A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | Y-mAbs Therapeutics, Inc. | $13,151 | 0 |
| A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma | Y-mAbs Therapeutics, Inc. | $12,600 | 0 |
| PHASE II STUDY OF HU3F8, IRINOTECAN/TEMOZOLOMIDE AND SARGRAMOSTIM (HITS) CHEMOIMMUNOTHERAPY FOR HIGH-RISK NEUROBLASTOMA | Y-mAbs Therapeutics, Inc. | $11,712 | 0 |
| HU3F8/GM-CSF IMMUNOTHERAPY PLUS ISOTRETINOIN FOR CONSOLIDATION OF FIRST REMISSION OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA: A PHASE II STUDY | Y-mAbs Therapeutics, Inc. | $9,588 | 0 |
| PHASE I STUDY OF HUMANIZED 3F8 MONOCLONAL ANTIBODY (HU3F8) IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AND GD2-POSITIVE TUMORS | Y-mAbs Therapeutics, Inc. | $7,084 | 0 |
| PHASE I/II STUDY OF COMBINATION THERAPY OF ANTIBODY HU3F8 WITH GRANULOCYTE- MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN PATIENTS WITH RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA | Y-mAbs Therapeutics, Inc. | $6,444 | 0 |
| PHASE I STUDY OF INTRATHECAL RADIOIMMUNOTHERAPY USING I-8H9 FOR CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL NEOPLASMS | Y-mAbs Therapeutics, Inc. | $5,000 | 0 |
Top Doctors Receiving Payments for DANYELZA — Page 10
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , F.N.P | Family | Los Angeles, CA | $31.57 | 1 |
| , PA-C | Physician Assistant | Los Angeles, CA | $31.57 | 1 |
| Kristen Mckenna | Physician Assistant | Los Angeles, CA | $31.57 | 1 |
| Emily Vargas Jimenez | Physician Assistant | Alhambra, CA | $31.57 | 1 |
| , MD | Pediatrics | New Orleans, LA | $31.34 | 1 |
| , M.D | Pediatric Hematology-Oncology | New Orleans, LA | $31.34 | 1 |
| , MD | Pediatrics | New Orleans, LA | $31.34 | 1 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $31.34 | 1 |
| , MD | Pediatrics | New Orleans, LA | $31.34 | 1 |
| Tasha Price | Family | Salt Lake City, UT | $31.10 | 1 |
| , APRN | Nurse Practitioner | Salt Lake City, UT | $31.10 | 1 |
| , PA-C | Physician Assistant | Salt Lake City, UT | $31.10 | 1 |
| , APRN, CPNP | Pediatrics | Las Vegas, NV | $30.88 | 1 |
| , APRN | Registered Nurse | Las Vegas, NV | $30.88 | 1 |
| Elizabeth Robbins | Registered Nurse | Las Vegas, NV | $30.88 | 1 |
| , APRN | Pediatrics | Las Vegas, NV | $30.88 | 1 |
| , DNP, FNP-BC, CPHON | Registered Nurse | Las Vegas, NV | $30.88 | 1 |
| , M.D | Pediatrics | San Bernardino, CA | $30.73 | 1 |
| , MD/PHD | Pediatric Hematology-Oncology | New Hyde Park, NY | $30.11 | 1 |
| , CPNP | Pediatrics | Shreveport, LA | $29.56 | 1 |
| , NP | Primary Care | Charlotte, NC | $26.44 | 1 |
| , NP | Nurse Practitioner | Charlotte, NC | $26.44 | 1 |
| , NP | Nurse Practitioner | Charlotte, NC | $26.44 | 1 |
| , NP | Pediatrics, Critical Care | Portland, OR | $25.56 | 1 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $25.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 312
- Transactions 576
About DANYELZA
DANYELZA is a drug associated with $2.4M in payments to 312 healthcare providers, recorded across 576 transactions in the CMS Open Payments database. The primary manufacturer is Y-mAbs Therapeutics, Inc..
Payment data is available from 2021 to 2024. In 2024, $1.1M was paid across 195 transactions to 130 doctors.
The most common payment nature for DANYELZA is "Unspecified" ($1.9M, 77.9% of total).
DANYELZA is associated with 16 research studies, including "NAXITAMAB ADDED TO INDUCTION FOR NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA" ($1.0M).